Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform
April 13 2023 - 9:44AM
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology
company specializing in AI-powered immunotherapies, announces the
successful publication in Frontiers of Immunology of preclinical
data demonstrating the effectiveness of its proprietary AI-driven
viral vaccine discovery platform. The presented preclinical study
was conducted in collaboration with associate professor Girish
Kirimanjeswara, Pennsylvania State University, US.
The published data showcase how Evaxion's proprietary
AI-platform, RAVEN (Rapidly Adaptive Viral Response), identifies
broad and robust T-cell epitopes from SARS-CoV-2 that protect
against mortality and severe disease in a COVID-19 mouse model.
This research demonstrates the potential of the RAVEN platform to
accelerate the development of effective viral vaccines, leveraging
the power of artificial intelligence.
"Our RAVEN platform represents a paradigm shift in vaccine
development, identifying vaccine candidates against any existing,
newly emerging, and mutating viral diseases tailored to any human
target population to secure broader and more durable protection,"
said Birgitte Rønø, Chief Scientific Officer of Evaxion. "This
positive preclinical data affirms our ability to select the right
T-cell epitopes, ultimately resulting in better vaccines for
patients. We remain committed to further advancing our AI-driven
viral vaccine discovery platform and collaborating with key
partners to translate our findings into tangible solutions for
addressing global health challenges."
RAVEN enables discovery of novel T-cell epitopes for any viral
disease with the potential of enhancing the efficacy of new and
existing B-cell vaccines and addresses the issues of fading
efficacy and evasion for many viral vaccines.
“To our knowledge, this study is the first to show in vivo
protection against severe COVID-19 by an AI-designed T-cell
vaccine,” said Dr. Kirimanjeswara. “The vaccine was extremely
effective at preventing severe COVID-19 in mice. This research also
paves the way for the potential rapid design of novel T-cell
vaccines against emerging and seasonal viral diseases, like
influenza,” said Dr. Kirimanjeswara.
Evaxion's AI-driven viral vaccine discovery platforms have the
potential to significantly shorten the vaccine discovery timeline
and enhance the efficiency of vaccine development, leading to the
development of safe and effective vaccines in a shorter timeframe.
With its innovative approach, Evaxion is at the forefront of
vaccine target discovery using artificial intelligence.
For more information about our publication, please
visit:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1166546
Innovation Fund Denmark supported this research.
About EvaxionEvaxion Biotech A/S is a clinical-stage biotech
company developing AI-powered immunotherapies. Evaxion’s
proprietary and scalable AI technologies decode the human immune
system to discover and develop novel immunotherapies for cancer,
bacterial diseases, and viral infections. Evaxion has a broad
pipeline of product candidates, including three personalized cancer
immunotherapies. The company is located in Hørsholm, Denmark, with
50 employees and is listed on the Nasdaq New York stock exchange.
For more information, please
visit: www.evaxion-biotech.com.
Source: Evaxion Biotech
Forward-looking statementThis announcement contains
forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The
words “target,” “believe,” “expect,” “hope,” “aim,” “intend,”
“may,” “might,” “anticipate,” “contemplate,” “continue,”
“estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can
have,” “likely,” “should,” “would,” “could,” and other words and
terms of similar meaning identify forward-looking
statements. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
factors, including, but not limited to, risks related to: our
financial condition and need for additional capital; our
development work; cost and success of our product development
activities and preclinical and clinical trials; commercializing any
approved pharmaceutical product developed using our AI platform
technology, including the rate and degree of market acceptance of
our product candidates; our dependence on third parties including
for conduct of clinical testing and product manufacture; our
inability to enter into partnerships; government regulation;
protection of our intellectual property rights; employee matters
and managing growth; our ADSs and ordinary shares, the impact
of international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on
our business from the worldwide COVID-19 pandemic and the
ongoing conflict in the region
surrounding Ukraine and Russia; and other
uncertainties affecting our business operations and financial
condition. For a further discussion of these risks, please
refer to the risk factors included in our most recent Annual Report
on Form 20-F and other filings with the U.S. Securities
and Exchange Commission (SEC), which are available
at www.sec.gov. We do not assume any obligation to update
any forward-looking statements except as required by law.
For more information
Evaxion Biotech A/S
Per Norlén
PNO@evaxion-biotech.com
+45 53 53 49 13
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jul 2023 to Jul 2024